Phase 2 Leukaemia Trial, Recruiting (NCT04895436)

Phase 2 Leukaemia Trial, Recruiting NCT04895436 Sponsor: AbbVie Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT04895436 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been formally diagnosed with chronic lymphocytic leukemia (CLL) — a type of blood cancer — and whose condition now needs treatment based on internationally recognised medical guidelines.
People who previously completed a first-line (initial) treatment course combining a drug called venetoclax with a type of immune-targeting drug (anti-CD20 antibody), possibly alongside another treatment, and whose CLL responded to that treatment (showed signs of remission or reduction).
People whose CLL came back more than 24 months after their last dose of venetoclax (Cohort 1), or between 12 and 24 months after their last dose of venetoclax (Cohort 2).

Who may not be able to join:

People who received any additional CLL treatment after finishing their venetoclax-based first-line course and before their CLL came back.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Australian sites

Royal Adelaide Hospital /ID# 229898, Adelaide, South Australia

Northern Hospital Epping /ID# 229847, Epping, Victoria

Peter MacCallum Cancer Ctr /ID# 254634, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04895436

Sponsor: AbbVie

Phase: Phase 2

Status: Recruiting

Condition: Leukaemia

Trial contact: 844-663-3742

More information: https://clinicaltrials.gov/study/NCT04895436

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been formally diagnosed with chronic lymphocytic leukemia (CLL) — a type of blood cancer — and whose condition now needs treatment based on internationally recognised medical guidelines.
People who previously completed a first-line (initial) treatment course combining a drug called venetoclax with a type of immune-targeting drug (anti-CD20 antibody), possibly alongside another treatment, and whose CLL responded to that treatment (showed signs of remission or reduction).
People whose CLL came back more than 24 months after their last dose of venetoclax (Cohort 1), or between 12 and 24 months after their last dose of venetoclax (Cohort 2).

Who may not be able to join:

People who received any additional CLL treatment after finishing their venetoclax-based first-line course and before their CLL came back.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

28 March 2022

Est. completion

1 November 2026

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇷 Brazil 🇧🇬 Bulgaria 🇩🇪 Germany 🇮🇱 Israel 🇮🇹 Italy 🇷🇴 Romania 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall response (OR) in Cohort 1 after end of combination treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov